Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam.
Identifieur interne : 002861 ( PubMed/Curation ); précédent : 002860; suivant : 002862Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam.
Auteurs : Thuy Thi Thanh Hoang [Viêt Nam] ; Nhung Viet Nguyen [Viêt Nam] ; Sy Ngoc Dinh [Viêt Nam] ; Hoa Binh Nguyen [Viêt Nam] ; Frank Cobelens [Pays-Bas] ; Guy Thwaites [Viêt Nam] ; Huong Thien Nguyen [Viêt Nam] ; Anh Thu Nguyen [Australie] ; Pamela Wright [Pays-Bas] ; Heiman F L. Wertheim [Royaume-Uni]Source :
- BMC public health [ 1471-2458 ] ; 2015.
Descripteurs français
- KwdFr :
- Co-infection, Communication, Dépistage systématique, Expectoration, Groupes focalisés, Humains, Infections à VIH (), Mycobacterium tuberculosis, Politique de santé, Prise en charge de la maladie, Rifampicine (usage thérapeutique), Secteur privé, Tuberculose multirésistante (), Tuberculose multirésistante (diagnostic), Tuberculose multirésistante (microbiologie), Tuberculose pulmonaire (), Tuberculose pulmonaire (diagnostic), Tuberculose pulmonaire (microbiologie), Vietnam.
- MESH :
- diagnostic : Tuberculose multirésistante, Tuberculose pulmonaire.
- microbiologie : Tuberculose multirésistante, Tuberculose pulmonaire.
- usage thérapeutique : Rifampicine.
- Co-infection, Communication, Dépistage systématique, Expectoration, Groupes focalisés, Humains, Infections à VIH, Mycobacterium tuberculosis, Politique de santé, Prise en charge de la maladie, Secteur privé, Tuberculose multirésistante, Tuberculose pulmonaire, Vietnam.
English descriptors
- KwdEn :
- Coinfection, Communication, Disease Management, Focus Groups, HIV Infections (complications), Health Policy, Humans, Mass Screening, Mycobacterium tuberculosis, Private Sector, Rifampin (therapeutic use), Sputum, Tuberculosis, Multidrug-Resistant (complications), Tuberculosis, Multidrug-Resistant (diagnosis), Tuberculosis, Multidrug-Resistant (microbiology), Tuberculosis, Multidrug-Resistant (therapy), Tuberculosis, Pulmonary (complications), Tuberculosis, Pulmonary (diagnosis), Tuberculosis, Pulmonary (microbiology), Tuberculosis, Pulmonary (therapy), Vietnam.
- MESH :
- chemical , therapeutic use : Rifampin.
- geographic : Vietnam.
- complications : HIV Infections, Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary.
- diagnosis : Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary.
- microbiology : Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary.
- therapy : Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary.
- Coinfection, Communication, Disease Management, Focus Groups, Health Policy, Humans, Mass Screening, Mycobacterium tuberculosis, Private Sector, Sputum.
Abstract
Vietnam is ranked 14(th) among 27 countries with high burden of multidrug-resistant tuberculosis (MDR-TB). In 2009, the Vietnamese government issued a policy on MDR-TB called Programmatic Management of Drug-resistant Tuberculosis (PMDT) to enhance and scale up diagnosis and treatment services for MDR-TB. Here we assess the PMDT performance in 2013 to determine the challenges to the successful identification and enrollment for treatment of MDR-TB in Vietnam.
DOI: 10.1186/s12889-015-2338-5
PubMed: 26415893
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002930
Links to Exploration step
pubmed:26415893Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam.</title>
<author><name sortKey="Hoang, Thuy Thi Thanh" sort="Hoang, Thuy Thi Thanh" uniqKey="Hoang T" first="Thuy Thi Thanh" last="Hoang">Thuy Thi Thanh Hoang</name>
<affiliation wicri:level="1"><nlm:affiliation>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi, Vietnam. hoangthanht@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Viêt Nam</country>
<wicri:regionArea>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nguyen, Nhung Viet" sort="Nguyen, Nhung Viet" uniqKey="Nguyen N" first="Nhung Viet" last="Nguyen">Nhung Viet Nguyen</name>
<affiliation wicri:level="1"><nlm:affiliation>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi, Vietnam. vietnhung@yahoo.com.</nlm:affiliation>
<country xml:lang="fr">Viêt Nam</country>
<wicri:regionArea>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dinh, Sy Ngoc" sort="Dinh, Sy Ngoc" uniqKey="Dinh S" first="Sy Ngoc" last="Dinh">Sy Ngoc Dinh</name>
<affiliation wicri:level="1"><nlm:affiliation>Vietnam Association for Tuberculosis and Lung Disease, Hanoi, Vietnam. syminhquan@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Viêt Nam</country>
<wicri:regionArea>Vietnam Association for Tuberculosis and Lung Disease, Hanoi</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nguyen, Hoa Binh" sort="Nguyen, Hoa Binh" uniqKey="Nguyen H" first="Hoa Binh" last="Nguyen">Hoa Binh Nguyen</name>
<affiliation wicri:level="1"><nlm:affiliation>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi, Vietnam. nguyenbinhhoatb@yahoo.com.</nlm:affiliation>
<country xml:lang="fr">Viêt Nam</country>
<wicri:regionArea>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cobelens, Frank" sort="Cobelens, Frank" uniqKey="Cobelens F" first="Frank" last="Cobelens">Frank Cobelens</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Global Health and Amsterdam Institute for Global Health and Development, Academic Medical Center, Amsterdam, Netherlands. f.cobelens@amc-cpcd.org.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Global Health and Amsterdam Institute for Global Health and Development, Academic Medical Center, Amsterdam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Thwaites, Guy" sort="Thwaites, Guy" uniqKey="Thwaites G" first="Guy" last="Thwaites">Guy Thwaites</name>
<affiliation wicri:level="1"><nlm:affiliation>Wellcome Trust Major Overseas Program, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam. gthwaites@oucru.org.</nlm:affiliation>
<country xml:lang="fr">Viêt Nam</country>
<wicri:regionArea>Wellcome Trust Major Overseas Program, Oxford University Clinical Research Unit, Ho Chi Minh City</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nguyen, Huong Thien" sort="Nguyen, Huong Thien" uniqKey="Nguyen H" first="Huong Thien" last="Nguyen">Huong Thien Nguyen</name>
<affiliation wicri:level="1"><nlm:affiliation>KNCV Tuberculosis Foundation, Vietnam Country Office, Hanoi, Vietnam. nthuong139@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Viêt Nam</country>
<wicri:regionArea>KNCV Tuberculosis Foundation, Vietnam Country Office, Hanoi</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nguyen, Anh Thu" sort="Nguyen, Anh Thu" uniqKey="Nguyen A" first="Anh Thu" last="Nguyen">Anh Thu Nguyen</name>
<affiliation wicri:level="1"><nlm:affiliation>Woolcock Institute Of Medical Research, Sydney, Australia. thuanh.nguyen@sydney.edu.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Woolcock Institute Of Medical Research, Sydney</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wright, Pamela" sort="Wright, Pamela" uniqKey="Wright P" first="Pamela" last="Wright">Pamela Wright</name>
<affiliation wicri:level="1"><nlm:affiliation>Medisch Comite Nederland-Vietnam, Amsterdam, Netherlands. pamela.wright@mcnv.nl.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Medisch Comite Nederland-Vietnam, Amsterdam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wertheim, Heiman F L" sort="Wertheim, Heiman F L" uniqKey="Wertheim H" first="Heiman F L" last="Wertheim">Heiman F L. Wertheim</name>
<affiliation wicri:level="1"><nlm:affiliation>Nuffield Department of Clinical Medicine, Centre for Tropical Medicine, University of Oxford, Oxford, United Kingdom. heiman.wertheim@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Nuffield Department of Clinical Medicine, Centre for Tropical Medicine, University of Oxford, Oxford</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26415893</idno>
<idno type="pmid">26415893</idno>
<idno type="doi">10.1186/s12889-015-2338-5</idno>
<idno type="wicri:Area/PubMed/Corpus">002930</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002930</idno>
<idno type="wicri:Area/PubMed/Curation">002861</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002861</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam.</title>
<author><name sortKey="Hoang, Thuy Thi Thanh" sort="Hoang, Thuy Thi Thanh" uniqKey="Hoang T" first="Thuy Thi Thanh" last="Hoang">Thuy Thi Thanh Hoang</name>
<affiliation wicri:level="1"><nlm:affiliation>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi, Vietnam. hoangthanht@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Viêt Nam</country>
<wicri:regionArea>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nguyen, Nhung Viet" sort="Nguyen, Nhung Viet" uniqKey="Nguyen N" first="Nhung Viet" last="Nguyen">Nhung Viet Nguyen</name>
<affiliation wicri:level="1"><nlm:affiliation>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi, Vietnam. vietnhung@yahoo.com.</nlm:affiliation>
<country xml:lang="fr">Viêt Nam</country>
<wicri:regionArea>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dinh, Sy Ngoc" sort="Dinh, Sy Ngoc" uniqKey="Dinh S" first="Sy Ngoc" last="Dinh">Sy Ngoc Dinh</name>
<affiliation wicri:level="1"><nlm:affiliation>Vietnam Association for Tuberculosis and Lung Disease, Hanoi, Vietnam. syminhquan@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Viêt Nam</country>
<wicri:regionArea>Vietnam Association for Tuberculosis and Lung Disease, Hanoi</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nguyen, Hoa Binh" sort="Nguyen, Hoa Binh" uniqKey="Nguyen H" first="Hoa Binh" last="Nguyen">Hoa Binh Nguyen</name>
<affiliation wicri:level="1"><nlm:affiliation>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi, Vietnam. nguyenbinhhoatb@yahoo.com.</nlm:affiliation>
<country xml:lang="fr">Viêt Nam</country>
<wicri:regionArea>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cobelens, Frank" sort="Cobelens, Frank" uniqKey="Cobelens F" first="Frank" last="Cobelens">Frank Cobelens</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Global Health and Amsterdam Institute for Global Health and Development, Academic Medical Center, Amsterdam, Netherlands. f.cobelens@amc-cpcd.org.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Global Health and Amsterdam Institute for Global Health and Development, Academic Medical Center, Amsterdam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Thwaites, Guy" sort="Thwaites, Guy" uniqKey="Thwaites G" first="Guy" last="Thwaites">Guy Thwaites</name>
<affiliation wicri:level="1"><nlm:affiliation>Wellcome Trust Major Overseas Program, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam. gthwaites@oucru.org.</nlm:affiliation>
<country xml:lang="fr">Viêt Nam</country>
<wicri:regionArea>Wellcome Trust Major Overseas Program, Oxford University Clinical Research Unit, Ho Chi Minh City</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nguyen, Huong Thien" sort="Nguyen, Huong Thien" uniqKey="Nguyen H" first="Huong Thien" last="Nguyen">Huong Thien Nguyen</name>
<affiliation wicri:level="1"><nlm:affiliation>KNCV Tuberculosis Foundation, Vietnam Country Office, Hanoi, Vietnam. nthuong139@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Viêt Nam</country>
<wicri:regionArea>KNCV Tuberculosis Foundation, Vietnam Country Office, Hanoi</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nguyen, Anh Thu" sort="Nguyen, Anh Thu" uniqKey="Nguyen A" first="Anh Thu" last="Nguyen">Anh Thu Nguyen</name>
<affiliation wicri:level="1"><nlm:affiliation>Woolcock Institute Of Medical Research, Sydney, Australia. thuanh.nguyen@sydney.edu.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Woolcock Institute Of Medical Research, Sydney</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wright, Pamela" sort="Wright, Pamela" uniqKey="Wright P" first="Pamela" last="Wright">Pamela Wright</name>
<affiliation wicri:level="1"><nlm:affiliation>Medisch Comite Nederland-Vietnam, Amsterdam, Netherlands. pamela.wright@mcnv.nl.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Medisch Comite Nederland-Vietnam, Amsterdam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wertheim, Heiman F L" sort="Wertheim, Heiman F L" uniqKey="Wertheim H" first="Heiman F L" last="Wertheim">Heiman F L. Wertheim</name>
<affiliation wicri:level="1"><nlm:affiliation>Nuffield Department of Clinical Medicine, Centre for Tropical Medicine, University of Oxford, Oxford, United Kingdom. heiman.wertheim@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Nuffield Department of Clinical Medicine, Centre for Tropical Medicine, University of Oxford, Oxford</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">BMC public health</title>
<idno type="eISSN">1471-2458</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coinfection</term>
<term>Communication</term>
<term>Disease Management</term>
<term>Focus Groups</term>
<term>HIV Infections (complications)</term>
<term>Health Policy</term>
<term>Humans</term>
<term>Mass Screening</term>
<term>Mycobacterium tuberculosis</term>
<term>Private Sector</term>
<term>Rifampin (therapeutic use)</term>
<term>Sputum</term>
<term>Tuberculosis, Multidrug-Resistant (complications)</term>
<term>Tuberculosis, Multidrug-Resistant (diagnosis)</term>
<term>Tuberculosis, Multidrug-Resistant (microbiology)</term>
<term>Tuberculosis, Multidrug-Resistant (therapy)</term>
<term>Tuberculosis, Pulmonary (complications)</term>
<term>Tuberculosis, Pulmonary (diagnosis)</term>
<term>Tuberculosis, Pulmonary (microbiology)</term>
<term>Tuberculosis, Pulmonary (therapy)</term>
<term>Vietnam</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Co-infection</term>
<term>Communication</term>
<term>Dépistage systématique</term>
<term>Expectoration</term>
<term>Groupes focalisés</term>
<term>Humains</term>
<term>Infections à VIH ()</term>
<term>Mycobacterium tuberculosis</term>
<term>Politique de santé</term>
<term>Prise en charge de la maladie</term>
<term>Rifampicine (usage thérapeutique)</term>
<term>Secteur privé</term>
<term>Tuberculose multirésistante ()</term>
<term>Tuberculose multirésistante (diagnostic)</term>
<term>Tuberculose multirésistante (microbiologie)</term>
<term>Tuberculose pulmonaire ()</term>
<term>Tuberculose pulmonaire (diagnostic)</term>
<term>Tuberculose pulmonaire (microbiologie)</term>
<term>Vietnam</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Rifampin</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Vietnam</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term>
<term>Tuberculosis, Multidrug-Resistant</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Tuberculosis, Multidrug-Resistant</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tuberculose multirésistante</term>
<term>Tuberculose pulmonaire</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Tuberculose multirésistante</term>
<term>Tuberculose pulmonaire</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Tuberculosis, Multidrug-Resistant</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Tuberculosis, Multidrug-Resistant</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Rifampicine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Coinfection</term>
<term>Communication</term>
<term>Disease Management</term>
<term>Focus Groups</term>
<term>Health Policy</term>
<term>Humans</term>
<term>Mass Screening</term>
<term>Mycobacterium tuberculosis</term>
<term>Private Sector</term>
<term>Sputum</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Co-infection</term>
<term>Communication</term>
<term>Dépistage systématique</term>
<term>Expectoration</term>
<term>Groupes focalisés</term>
<term>Humains</term>
<term>Infections à VIH</term>
<term>Mycobacterium tuberculosis</term>
<term>Politique de santé</term>
<term>Prise en charge de la maladie</term>
<term>Secteur privé</term>
<term>Tuberculose multirésistante</term>
<term>Tuberculose pulmonaire</term>
<term>Vietnam</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Vietnam is ranked 14(th) among 27 countries with high burden of multidrug-resistant tuberculosis (MDR-TB). In 2009, the Vietnamese government issued a policy on MDR-TB called Programmatic Management of Drug-resistant Tuberculosis (PMDT) to enhance and scale up diagnosis and treatment services for MDR-TB. Here we assess the PMDT performance in 2013 to determine the challenges to the successful identification and enrollment for treatment of MDR-TB in Vietnam.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26415893</PMID>
<DateCreated><Year>2015</Year>
<Month>09</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>05</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>22</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2458</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>15</Volume>
<PubDate><Year>2015</Year>
<Month>Sep</Month>
<Day>29</Day>
</PubDate>
</JournalIssue>
<Title>BMC public health</Title>
<ISOAbbreviation>BMC Public Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam.</ArticleTitle>
<Pagination><MedlinePgn>980</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/s12889-015-2338-5</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Vietnam is ranked 14(th) among 27 countries with high burden of multidrug-resistant tuberculosis (MDR-TB). In 2009, the Vietnamese government issued a policy on MDR-TB called Programmatic Management of Drug-resistant Tuberculosis (PMDT) to enhance and scale up diagnosis and treatment services for MDR-TB. Here we assess the PMDT performance in 2013 to determine the challenges to the successful identification and enrollment for treatment of MDR-TB in Vietnam.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">In 35 provinces implementing PMDT, we quantified the number of MDR-TB presumptive patients tested for MDR-TB by Xpert MTB/RIF and the number of MDR-TB patients started on second-line treatment. In addition, existing reports and documents related to MDR-TB policies and guidelines in Vietnam were reviewed, supplemented with focus group discussions and in-depth interviews with MDR-TB key staff members.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">5,668 (31.2 %) of estimated 18,165 MDR-TB presumptive cases were tested by Xpert MTB/RIF and second-line treatment was provided to 948 out of 5100 (18.7 %) of MDR-TB patients. Those tested for MDR-TB were 340/3224 (10.5 %) of TB-HIV co-infected patients and 290/2214 (13.1 %) of patients who remained sputum smear-positive after 2 and 3 months of category I TB regimen. Qualitative findings revealed the following challenges to detection and enrollment of MDR-TB in Vietnam: insufficient TB screening capacity at district hospitals where TB units were not available and poor communication and implementation of policy changes. Instructions for policy changes were not always received, and training was inconsistent between training courses. The private sector did not adequately report MDR-TB cases to the NTP.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The proportion of MDR-TB patients diagnosed and enrolled for second-line treatment is less than 20 % of the estimated total. The low enrollment is largely due to the fact that many patients at risk are missed for MDR-TB screening. In order to detect more MDR-TB cases, Vietnam should intensify case finding of MDR-TB by a comprehensive strategy to screen for MDR-TB among new cases rather than targeting previously treated cases, in particular those with HIV co-infection and contacts of MDR-TB patients, and should engage the private sector in PMDT.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoang</LastName>
<ForeName>Thuy Thi Thanh</ForeName>
<Initials>TT</Initials>
<AffiliationInfo><Affiliation>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi, Vietnam. hoangthanht@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nguyen</LastName>
<ForeName>Nhung Viet</ForeName>
<Initials>NV</Initials>
<AffiliationInfo><Affiliation>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi, Vietnam. vietnhung@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dinh</LastName>
<ForeName>Sy Ngoc</ForeName>
<Initials>SN</Initials>
<AffiliationInfo><Affiliation>Vietnam Association for Tuberculosis and Lung Disease, Hanoi, Vietnam. syminhquan@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nguyen</LastName>
<ForeName>Hoa Binh</ForeName>
<Initials>HB</Initials>
<AffiliationInfo><Affiliation>National Tuberculosis Control Program of Vietnam- National Lung Hospital (VNTP-NLH), Hanoi, Vietnam. nguyenbinhhoatb@yahoo.com.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, Paris, France. nguyenbinhhoatb@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cobelens</LastName>
<ForeName>Frank</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Global Health and Amsterdam Institute for Global Health and Development, Academic Medical Center, Amsterdam, Netherlands. f.cobelens@amc-cpcd.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thwaites</LastName>
<ForeName>Guy</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Wellcome Trust Major Overseas Program, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam. gthwaites@oucru.org.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Nuffield Department of Clinical Medicine, Centre for Tropical Medicine, University of Oxford, Oxford, United Kingdom. gthwaites@oucru.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nguyen</LastName>
<ForeName>Huong Thien</ForeName>
<Initials>HT</Initials>
<AffiliationInfo><Affiliation>KNCV Tuberculosis Foundation, Vietnam Country Office, Hanoi, Vietnam. nthuong139@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nguyen</LastName>
<ForeName>Anh Thu</ForeName>
<Initials>AT</Initials>
<AffiliationInfo><Affiliation>Woolcock Institute Of Medical Research, Sydney, Australia. thuanh.nguyen@sydney.edu.au.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wright</LastName>
<ForeName>Pamela</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Medisch Comite Nederland-Vietnam, Amsterdam, Netherlands. pamela.wright@mcnv.nl.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wertheim</LastName>
<ForeName>Heiman F L</ForeName>
<Initials>HF</Initials>
<AffiliationInfo><Affiliation>Nuffield Department of Clinical Medicine, Centre for Tropical Medicine, University of Oxford, Oxford, United Kingdom. heiman.wertheim@gmail.com.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Wellcome Trust Major Overseas Program, Oxford University Clinical Research Unit, (OUCRU), Hanoi, Vietnam. heiman.wertheim@gmail.com.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Medical Microbiology, Radboudumc, Nijmegen, Netherlands. heiman.wertheim@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>089276</GrantID>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D023362">Evaluation Studies</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>09</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>BMC Public Health</MedlineTA>
<NlmUniqueID>100968562</NlmUniqueID>
<ISSNLinking>1471-2458</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>VJT6J7R4TR</RegistryNumber>
<NameOfSubstance UI="D012293">Rifampin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2014 Feb;52(2):635-7</RefSource>
<PMID Version="1">24478501</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Respir J. 2014 Dec;44(6):1711-3</RefSource>
<PMID Version="1">25186257</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Respir Crit Care Med. 1996 Jan;153(1):317-24</RefSource>
<PMID Version="1">8542137</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Indian J Chest Dis Allied Sci. 2012 Jan-Mar;54(1):23-6</RefSource>
<PMID Version="1">22779119</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2013 Aug;13(8):690-7</RefSource>
<PMID Version="1">23743044</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017144" MajorTopicYN="N">Focus Groups</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006291" MajorTopicYN="Y">Health Policy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008403" MajorTopicYN="Y">Mass Screening</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009169" MajorTopicYN="N">Mycobacterium tuberculosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017149" MajorTopicYN="N">Private Sector</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012293" MajorTopicYN="N">Rifampin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013183" MajorTopicYN="N">Sputum</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018088" MajorTopicYN="N">Tuberculosis, Multidrug-Resistant</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014397" MajorTopicYN="N">Tuberculosis, Pulmonary</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014744" MajorTopicYN="N" Type="Geographic">Vietnam</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4587724</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>03</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>09</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>9</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>9</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>5</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26415893</ArticleId>
<ArticleId IdType="doi">10.1186/s12889-015-2338-5</ArticleId>
<ArticleId IdType="pii">10.1186/s12889-015-2338-5</ArticleId>
<ArticleId IdType="pmc">PMC4587724</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002861 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002861 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:26415893 |texte= Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26415893" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |